What is the best management option for a 56-year-old patient with a history of acute pancreatitis who presents with a 2.5cm splenic artery aneurysm with calcification?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Article Review Status
Submitted
Under Review
Approved

Last updated: May 9, 2025 • View editorial policy

From the Guidelines

The best management option for a 56-year-old patient with a history of acute pancreatitis who has a 2.5 cm calcified splenic artery aneurysm is splenectomy with removal of the affected artery (option C). This is because the aneurysm is large (≥2 cm) and calcified, which increases the rupture risk, and the patient has a history of pancreatitis, a known risk factor for both aneurysm formation and rupture 1. Some key points to consider in this case include:

  • The size of the aneurysm: aneurysms larger than 2 cm carry a significant rupture risk of 10-25%, with mortality rates of 25-70% if rupture occurs 1.
  • The presence of calcification: this indicates chronic disease and potential wall weakening, further increasing the rupture risk.
  • The history of pancreatitis: this is a known risk factor for both aneurysm formation and rupture.
  • The potential consequences of rupture: these can be severe, with high mortality rates, and include the "double rupture phenomenon" where an initial small bleed is followed by a major rupture with rapid intra-abdominal bleeding and haemorrhagic shock 1. Splenectomy with removal of the affected artery (option C) would be the most definitive treatment in this scenario, as it eliminates both the aneurysm and the risk of collateral vessel formation that could lead to recurrence 1. Following splenectomy, the patient would require appropriate vaccinations against encapsulated organisms and lifelong antibiotic prophylaxis to prevent overwhelming post-splenectomy infection. Observation (option A) is not appropriate given the high rupture risk, and ligation of the aneurysm (option B) may not be as effective in preventing recurrence as splenectomy with removal of the affected artery.

From the Research

Management Options for Splenic Aneurysm

  • The patient has a history of acute pancreatitis and presents with a splenic aneurysm of 2.5cm with calcification.
  • Considering the size of the aneurysm and its potential for rupture, management options should be carefully evaluated.
  • According to the study by 2, splenic artery pseudoaneurysm is rare and usually a complication of pancreatitis or trauma, and the authors recommend repair of all splenic artery pseudoaneurysms.

Treatment Approaches

  • The study by 3 presents a case of a ruptured splenic artery aneurysm as a complication of acute pancreatitis, where the patient underwent immediate surgery with excision of the pseudoaneurysm, spleen, and part of the pancreatic tail.
  • Another approach is transcatheter embolization, as reported in the study by 4, where a 49-year-old male with recurrent pancreatitis and a splenic artery pseudoaneurysm underwent successful embolization with complete resolution of symptoms.
  • Splenectomy with removal of the affected artery is also a possible management option, as mentioned in the study by 2, where 4 patients underwent splenectomy and distal pancreatectomy.

Best Management Option

  • Based on the available evidence, the best management option for the patient with a 2.5cm splenic aneurysm and calcification would be either splenectomy with removal of the affected artery or transcatheter embolization, considering the patient's history of acute pancreatitis and the size of the aneurysm.
  • However, the final decision should be made by a specialist tertiary center, taking into account the patient's overall condition and the potential risks and benefits of each management option, as suggested by the study by 5.

References

Related Questions

What is the best management option for a 56-year-old patient with a history of acute pancreatitis who presents with a 2.5cm splenic artery aneurysm with calcification?
What is the appropriate treatment for a 28-year-old male with hypertension, tachycardia, and epigastric pain, with a history of alcohol use?
What is the management of acute pancreatitis due to Wegovy (semaglutide)?
What are the causes and symptoms of acute pancreatitis?
What is the Bush/Jacoby classification (Burch/Jacoby classification)?
What is the most likely underlying cause of a 4-year-old girl's presentation with rash, malaise, petechiae, diffuse abdominal tenderness, and schistocytes on peripheral blood smear, following a recent episode of diarrhea and a history of high fever with a rash, and having up-to-date vaccinations (vaccinations against common childhood diseases)?
What immunomodulating agent, administered via intramuscular (IM) injections, is prescribed for Gabriel, diagnosed with Hairy Cell Leukemia, given the options: Intron A (Interferon alfa-2b), Betaseron (Interferon beta-1b), Infergen (Interferon alfacon-1), Actimmune (Interferon gamma-1b)?
What type of amputation is indicated for an elderly diabetic patient with gangrene in the forefoot: A. Syme’s amputation (at the level of the ankle, preserving the heel pad), B. Transmetatarsal amputation, or C. Below-knee amputation?
What cytotoxic drug, such as Humira (adalimumab), Azathioprine, Filgrastim, or Arava (leflunomide), is prescribed to a patient diagnosed with Systemic Lupus Erythematosus (SLE)?
What is the treatment for flexor tenosynovitis?
What is the evidence to support return to work when chronic pain is the only symptom and there is no objective evidence of underlying pathology?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.